智翔金泰：自主研发赛立奇单抗纳入2025年国家医保目录

Core Viewpoint - The inclusion of the monoclonal antibody, Saliqi, in the National Medical Insurance Directory marks a significant milestone for Zhixiang Jintai, enhancing patient access to innovative domestic treatments and reducing out-of-pocket expenses for patients starting January 1, 2026 [1][2]. Group 1: Product Development and Approval - Saliqi is a recombinant fully human anti-IL-17A monoclonal antibody developed using a unique dual-carrier phage display technology platform, designed to inhibit inflammation by blocking the interaction between IL-17A and IL-17RA [1]. - Since its approval for market launch in August 2024, Saliqi has been authorized for the treatment of moderate to severe plaque psoriasis and ankylosing spondylitis, breaking the monopoly of foreign pharmaceutical companies in this treatment area [1]. Group 2: Clinical Research and Efficacy - In clinical trials, Saliqi demonstrated a 74.0% ASAS20 response rate at 16 weeks for patients receiving a 200mg dose for ankylosing spondylitis, significantly outperforming the placebo group [2]. - For moderate to severe plaque psoriasis, the drug showed a PASI75 response rate of 90.7% at 12 weeks and a PASI75 response rate of 96.5% at 52 weeks, with a relapse rate of only 0.4% [2]. Group 3: Market Impact and Accessibility - Saliqi has achieved market coverage across 30 provinces in China within its first year, benefiting over 10,000 patients, and its inclusion in the national insurance directory is expected to further enhance drug accessibility and affordability for patients [2]. - The company has committed to continuing its focus on patient needs and advancing the development of more internationally competitive innovative drugs, aiming to transition from "catching up" to "leading" in the domestic pharmaceutical market [3].